Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .

Trial Details

NCT ID
NCT05363280
Phase
PHASE2
Sponsor
Advenchen Pharmaceuticals, LLC.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • AL8326 40 mg
  • AL8326 60 mg
  • AL8326 80 mg--stopped
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Weston, Florida, United States|26.10037,-80.39977
  • Chicago, Illinois, United States|41.85003,-87.65005
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Male or female, 18 years of age or older
  • ECOG performance status of 0 or 1
  • Histologically or cytologically confirmed SCLC /NSCLC/RCC
  • Have at least 1 lesion that meets the criteria for being measurable, as defined by RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →